Literature DB >> 23989967

Pharmacokinetics of desmopressin administered as tablet and oral lyophilisate formulation in children with monosymptomatic nocturnal enuresis.

Pauline De Bruyne1, Ann De Guchtenaere, Charlotte Van Herzeele, Ann Raes, Jo Dehoorne, Piet Hoebeke, Erik Van Laecke, Johan Vande Walle.   

Abstract

Desmopressin 120 μg oral lyophilisate and 200 μg tablet are considered bioequivalent, based on extrapolation of studies in a limited number of adults and on one dose-finding study of desmopressin oral lyophilisate in children. However, no comparative pharmacokinetic study in children was executed confirming this statement. No data are available on the influence of food intake on the bioavailability of desmopressin tablet in a pediatric setting, although studies in adults have documented that food intake results in a significantly lower desmopressin plasma concentration. In this study, we analyzed plasma concentrations of desmopressin oral lyophilisate and tablet with concomitant food intake. Twenty-three children with monosymptomatic nocturnal enuresis (mean age, 12.7 years) were recruited. Two tests were performed on two separate days in identical conditions with a standardized food and fluid intake. Desmopressin was administered as desmopressin tablet or desmopressin oral lyophilisate immediately after a meal. Desmopressin plasma concentration was measured at 1 h, 2 h, and 6 h postdosing. No significant difference in plasma concentration of 120 μg desmopressin oral lyophilisate and 200 μg tablet was demonstrated, even with concomitant food intake. A significant difference in variability was found, identifying a smaller variance for desmopressin oral lyophilisate plasma concentrations at all time points. This study demonstrates comparable plasma levels for desmopressin oral lyophilisate, despite the lower dose. The dosage for desmopressin oral lyophilisate is more predictable due to the significantly smaller variance. Therefore, desmopressin oral lyophilisate seems more suitable, especially in the younger age group for which time interval between dinner and drug administration is limited.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23989967     DOI: 10.1007/s00431-013-2108-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

Review 1.  Nocturnal enuresis: an international evidence based management strategy.

Authors:  K Hjalmas; T Arnold; W Bower; P Caione; L M Chiozza; A von Gontard; S W Han; D A Husman; A Kawauchi; G LAckgren; H Lottmann; S Mark; S Rittig; L Robson; J Vande Walle; C K Yeung
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

2.  The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society.

Authors:  Tryggve Nevéus; Alexander von Gontard; Piet Hoebeke; Kelm Hjälmås; Stuart Bauer; Wendy Bower; Troels Munch Jørgensen; Søren Rittig; Johan Vande Walle; Chung-Kwong Yeung; Jens Christian Djurhuus
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

Review 3.  Therapeutic application of peptides and proteins: parenteral forever?

Authors:  Zuzana Antosova; Martina Mackova; Vladimir Kral; Tomas Macek
Journal:  Trends Biotechnol       Date:  2009-09-18       Impact factor: 19.536

4.  Desmopressin toxicity due to prolonged half-life in 18 patients with nocturnal enuresis.

Authors:  Jo L Dehoorne; Ann M Raes; Erik van Laecke; Piet Hoebeke; Johan G Vande Walle
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

Review 5.  Diabetes insipidus.

Authors:  P H Baylis; T Cheetham
Journal:  Arch Dis Child       Date:  1998-07       Impact factor: 3.791

6.  Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects.

Authors:  S Rittig; A R Jensen; K T Jensen; E B Pedersen
Journal:  Clin Endocrinol (Oxf)       Date:  1998-02       Impact factor: 3.478

Review 7.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

8.  The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis.

Authors:  S L Schulman; A Stokes; P M Salzman
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

9.  Self-image and performance in children with nocturnal enuresis.

Authors:  M Theunis; E Van Hoecke; S Paesbrugge; P Hoebeke; J Vande Walle
Journal:  Eur Urol       Date:  2002-06       Impact factor: 20.096

10.  A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis.

Authors:  Johan G J Vande Walle; Guy A Bogaert; Sven Mattsson; Thierry Schurmans; Piet Hoebeke; Veerle Deboe; Jens Peter Norgaard
Journal:  BJU Int       Date:  2006-03       Impact factor: 5.588

View more
  8 in total

1.  Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children.

Authors:  Robin Michelet; Lien Dossche; Pauline De Bruyne; Pieter Colin; Koen Boussery; Johan Vande Walle; Jan Van Bocxlaer; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

2.  Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Jan Van Bocxlaer; An Vermeulen; Johan Vande Walle
Journal:  Eur J Clin Pharmacol       Date:  2017-12-03       Impact factor: 2.953

3.  An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?

Authors:  Robin Michelet; Lien Dossche; Charlotte Van Herzeele; Pauline De Bruyne; Elke Gasthuys; Jan Van Bocxlaer; Johan Vande Walle; An Vermeulen
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

Review 4.  Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.

Authors:  Xinyi Chin; Shao Wei Teo; Soo Ting Lim; Yong Hong Ng; How Chuan Han; Fabian Yap
Journal:  Eur J Clin Pharmacol       Date:  2022-02-23       Impact factor: 2.953

Review 5.  The pathophysiology of monosymptomatic nocturnal enuresis with special emphasis on the circadian rhythm of renal physiology.

Authors:  L Dossche; J Vande Walle; C Van Herzeele
Journal:  Eur J Pediatr       Date:  2016-05-02       Impact factor: 3.183

6.  Solid lipid particles for oral delivery of peptide and protein drugs III - the effect of fed state conditions on the in vitro release and degradation of desmopressin.

Authors:  Philip C Christophersen; Dimple Vaghela; Anette Müllertz; Mingshi Yang; Hanne M Nielsen; Huiling Mu
Journal:  AAPS J       Date:  2014-05-30       Impact factor: 4.009

7.  Population Pharmacokinetic Modeling of a Desmopressin Oral Lyophilisate in Growing Piglets as a Model for the Pediatric Population.

Authors:  Elke Gasthuys; An Vermeulen; Siska Croubels; Joske Millecam; Stijn Schauvliege; Thomas van Bergen; Pauline De Bruyne; Johan Vande Walle; Mathias Devreese
Journal:  Front Pharmacol       Date:  2018-01-31       Impact factor: 5.810

Review 8.  Optimizing response to desmopressin in patients with monosymptomatic nocturnal enuresis.

Authors:  Konstantinos Kamperis; Charlotte Van Herzeele; Soren Rittig; Johan Vande Walle
Journal:  Pediatr Nephrol       Date:  2016-04-12       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.